GlaxoSmithKline could reportedly be targeted by Roche, Johnson & Johnson

Pharmaceuticals giant GlaxoSmithKline could reportedly become the latest takeover target in the industry.

According to the Daily Mail, market participants are speculating that the company may face an approach from Switzerland’s Roche or US company Johnson & Johnson at about 1900p per share.

Such a move would value GSK at more than £92bn.

Speaking over the weekend to Sharecast, Alistair McCaig, senior market analyst at IG, highlighted UK-listed pharmaceuticals as one of his favourites given the continuing need for American outfits to beef-up their product pipelines after a dearth of investment in recent years.